SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-20-000092
Filing Date
2020-08-07
Accepted
2020-08-07 16:52:12
Documents
64
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20200630.htm   iXBRL 10-Q 2274876
2 EX-31.1 exhibit311q22020.htm EX-31.1 12092
3 EX-31.2 exhibit312q22020.htm EX-31.2 12091
4 EX-32.1 exhibit321q22020.htm EX-32.1 7183
5 EX-32.2 exhibit322q22020.htm EX-32.2 7290
  Complete submission text file 0001714899-20-000092.txt   8095215

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20200630.xsd EX-101.SCH 47557
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20200630_cal.xml EX-101.CAL 69355
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20200630_def.xml EX-101.DEF 237790
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20200630_lab.xml EX-101.LAB 577376
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20200630_pre.xml EX-101.PRE 376007
11 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20200630_htm.xml XML 1428281
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 201085472
SIC: 2836 Biological Products, (No Diagnostic Substances)